Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type

American Journal of Hematology

Volumn 83, Issue 10, 2008, Pages 795-799

  Wang, Biyun ^a   Li, Xiao Qiu ^a   Ma, Xuejun ^a   Hong, Xiaonan ^a   Lu, Hongfen ^a   Guo, Ye ^a  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; GLYCOPROTEIN P; LOMUSTINE; MONOCLONAL ANTIBODY; NITROSOUREA; PREDNISONE; SEMUSTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORRELATION ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; NATURAL KILLER T CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL RATE; T CELL LYMPHOMA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KILLER CELLS, NATURAL; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; NOSE; NOSE NEOPLASMS; P-GLYCOPROTEIN; PREDNISONE; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 53549130011     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21256     Document Type: Article

References (27)

1. Chan JK, Jaffe ES, Ralfkiaer E. Extranodal NK/T-cell lymphoma, nasal type. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classification of Tumours. Lyon: IARC Press; 2001. pp 204-207.
2. Ko YH, Ree HJ, Kim WS, et al. Clinicopathologic and genotypic study of extranodal nasal-type natural killer/T-cell lymphoma and natural killer precursor lymphoma among Koreans. Cancer 2000;89:2106-2116.
3. Ng SB, Lai KW, Murugaya S, et al. Nasal-type extranodal natural killer/T-cell lymphomas: A clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol 2004;17:1097-1107.
4. Kanavaros P, Lescs MC, Brière J, et al. Nasal T-cell lymphoma: A clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 1993;81:2688-2695.
5. Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study. J Clin Oncol 2006;24:612-618.
6. Kim WS, Song SY, Ahn YC, et al. CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 2001;12:349-352.
7. Lee SH, Ahn YC, Kim WS, et al. The effect of pre-irradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphoma. Haematologica 2006;91:427-428.
8. Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006;24:181-189.
9. Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004;22:3032-3038.
10. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-627.
11. Marie JP. Drug resistance in hematologic malignancies. Curr Opin Oncol 2001;13:463-469.
12. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993;81:2215-2222.
13. Marie JP, Zhou DC, Gurbuxani S, et al. MDR1/P-glycoprotein in haematological neoplasms. Eur J Cancer 1996;32A:1034-1038.
14. Kobayashi Y, Yamashiro T, Nagatake H, et al. Expression and function of multidrug resistance P-glycoprotein in a cultured natural killer cell-rich population revealed by MRK16 monoclonal antibody and AHC-52. Biochem Pharmacol 1994;48:1641-1646.
15. Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995;76:2351-2356.
16. Drénou B, Lamy T, Amiot L, et al. CD3- CD56+ non-Hodgkin's lymphomas with an aggressive behavior related to multidrug resistance. Blood 1997;89:2966-2974.
17. Egashira M, Kawamata N, Sugimoto K, et al. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 1999;93:599-606.
18. Kim TM, Park YH, Lee SY, et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood 2005;106:3785-3790.
19. Jung CK, Lee KY, Kim Y, et al. Epstein-Barr virus infection, drug resistance and prognosis in Korean T- and NK-cell lymphomas. Pathol Int 2001;51:355-363.
20. Kim GE, Yang WI, Lee SW, et al. Lack of correlation between P-glycoprotein and chemotherapy resistance in nasal NK/T-cell lymphomas. Leuk Lymphoma 2004;45:1857-1864.
21. van der Valk P, van Kalken CK, Ketelaars H, et al. Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule. Ann Oncol 1990;1:56-64.
22. Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations. Cancer Res 1996;56:3010-3020.
23. Gala JL, McLachlan JM, Bell DR, et al. Specificity and sensitivity of immunocytochemistry for detecting P-glycoprotein in haematological malignancies. J Clin Pathol 1994;47:619-624.
24. Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med 2000;247:521-534.
25. Lee KW, Yun T, Kim DW, et al. First-line ifosfamide, methotrexate, etoposide and prednisolone chemotherapy +/- radiotherapy is active in stage I/II extranodal NK/T-cell lymphoma. Leuk Lymphoma 2006;47:1274-1282.
26. Guo Y, Lu JJ, Ma X, et al. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: Elucidating the significance of systemic chemotherapy. Oral Oncol 2008;44:23-30.
27. Ohsawa M, Ikura Y, Fukushima H, et al. Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma. Oncology 2005;68:422-431.